share_log

Medtronic | 10-Q: Q2 2025 Earnings Report

Medtronic | 10-Q: Q2 2025 Earnings Report

美敦力 | 10-Q：2025财年二季报
美股SEC公告 ·  2024/11/27 05:18

Moomoo AI 已提取核心信息

Medtronic reported Q2 FY2025 revenue of $8.4 billion, up 5% year-over-year, with GAAP diluted EPS rising to $0.99 from $0.68. Cardiovascular segment revenue grew 6% to $3.1 billion, driven by strong performance in TAVR and Cardiac Rhythm Management. Neuroscience revenue increased 7% to $2.5 billion, boosted by growth in Neuromodulation and Spine products.The company's Medical Surgical segment revenue rose 1% to $2.1 billion, while Diabetes revenue surged 12% to $686 million, propelled by strong U.S. adoption of the MiniMed 780G automated insulin delivery system. Medtronic's gross margin decreased slightly due to unfavorable currency impact, but operating cash flow improved to $1.9 billion for the first half of the fiscal year.Looking ahead, Medtronic remains focused on innovation and expanding its product pipeline. The company highlighted ongoing clinical trials and recent regulatory approvals, including the U.S. FDA approval of Asleep DBS surgery for Parkinson's and essential tremor patients. Medtronic also noted potential impacts from the implementation of global minimum tax rules and ongoing legal proceedings in various jurisdictions.
Medtronic reported Q2 FY2025 revenue of $8.4 billion, up 5% year-over-year, with GAAP diluted EPS rising to $0.99 from $0.68. Cardiovascular segment revenue grew 6% to $3.1 billion, driven by strong performance in TAVR and Cardiac Rhythm Management. Neuroscience revenue increased 7% to $2.5 billion, boosted by growth in Neuromodulation and Spine products.The company's Medical Surgical segment revenue rose 1% to $2.1 billion, while Diabetes revenue surged 12% to $686 million, propelled by strong U.S. adoption of the MiniMed 780G automated insulin delivery system. Medtronic's gross margin decreased slightly due to unfavorable currency impact, but operating cash flow improved to $1.9 billion for the first half of the fiscal year.Looking ahead, Medtronic remains focused on innovation and expanding its product pipeline. The company highlighted ongoing clinical trials and recent regulatory approvals, including the U.S. FDA approval of Asleep DBS surgery for Parkinson's and essential tremor patients. Medtronic also noted potential impacts from the implementation of global minimum tax rules and ongoing legal proceedings in various jurisdictions.
美敦力报告2025财年第二季度营业收入为84亿，较去年增长5%，GAAP摊薄后每股收益从0.68上涨至0.99。心血管部门营业收入增长6%至31亿，这得益于TAVR和心脏节律管理领域的强劲表现。神经科学营业收入增长7%至25亿，受到神经调节和脊柱产品增长的推动。公司医疗外科部门营业收入上升1%至21亿，而糖尿病部门的营业收入猛增12%至68600万，这主要是由于MiniMed 780G自动胰岛素输送系统在美国的强劲采用。美敦力的毛利率略微下降，主要受到不利货币影响的影响，但上半财年的经营现金流改善至19亿。展望未来，美敦力仍专注于创新和扩大产品管道。公司强调了正在进行的临床试验和最近的监管批准，包括美国FDA对帕金森病和特发性震颤患者的Asleep DBS手术的批准。美敦力还指出了全球最低税规则实施和各地区正在进行的法律程序可能带来的影响。
美敦力报告2025财年第二季度营业收入为84亿，较去年增长5%，GAAP摊薄后每股收益从0.68上涨至0.99。心血管部门营业收入增长6%至31亿，这得益于TAVR和心脏节律管理领域的强劲表现。神经科学营业收入增长7%至25亿，受到神经调节和脊柱产品增长的推动。公司医疗外科部门营业收入上升1%至21亿，而糖尿病部门的营业收入猛增12%至68600万，这主要是由于MiniMed 780G自动胰岛素输送系统在美国的强劲采用。美敦力的毛利率略微下降，主要受到不利货币影响的影响，但上半财年的经营现金流改善至19亿。展望未来，美敦力仍专注于创新和扩大产品管道。公司强调了正在进行的临床试验和最近的监管批准，包括美国FDA对帕金森病和特发性震颤患者的Asleep DBS手术的批准。美敦力还指出了全球最低税规则实施和各地区正在进行的法律程序可能带来的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间